Clinical trials: Wart
Papillomatosis, HIV Infections
Treatment of Oral Warts in HIV+ Patients
This is a study to test lozenges of interferon-alpha that are dissolved in the mouth as a treatment of oral warts in HIV-positive adults.
- Trial name
- NCT00454181
- Testing
- Interferon-alpha
- Where
- 12 sites in United States
- Volunteers
- 59 people
- Sponsor
- Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Cervical Cancer, Vulvar Cancer
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
The purpose of this study was to evaluate the safety, efficacy, and immunogenicity of V503 in comparison to GARDASIL. The primary hypotheses tested in the study were 1) V503 administered to 16- to 26-year-old adolescents and…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT00543543
- Testing
- Comparator: GARDASIL, Experimental: V503
- Volunteers
- 14,840 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Genital Warts
Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts
Large genital warts are frequently diagnosed in general gynaecology and oncology clinics in South Africa. Medical and destructive therapy for small warts is generally very effective, however unique problems posed by large or…
- Trial name
- TheraVACCS (NCT02750202)
- Testing
- Quadrivalent HPV vaccine, Hepatitis B vaccine
- Where
- 2 sites in South Africa
- Volunteers
- 52 people
- Sponsor
- University of Pretoria
Myelokathexis, Infections
Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome
Background: WHIMS (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome) is a rare disease. It can cause cancers, infections, and warts. Researchers want to see if a drug called plerixafor can treat WHIMS.
- Conditions
- Myelokathexis, Infections, Neutropenia, Warts
- Trial name
- NCT02231879
- Testing
- Plerixafor, G-CSF
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infertility
Follicular Activation in Poor Responders
This study aims to assess whether activation of primordial follicles through ovarian cortex fragmentation may increase the number of antral follicles present in the ovary of patients with diminished ovarian reserve.
- Trial name
- FAPPOR (NCT02354963)
- Testing
- In vitro fragmentation of the ovarian tissue
- Where
- Spain
- Volunteers
- 34 people
- Sponsor
- César Díaz García
HIV Positive, Anal Condylomata
The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata
The primary objective of this pilot study is to evaluate the effect of the HPV vaccine Gardasil on anal condylomata recurrence and persistence rates in HIV positive patients.
- Conditions
- HIV Positive, Anal Condylomata, Anal Warts, HIV Infections
- Trial name
- NCT00941889
- Testing
- Saline, Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Washington University School of Medicine
Papillomavirus Infections
GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
The study is designed to determine the safety, tolerability and immunogenicity of a 3-dose regimen of GARDASIL™ administered to healthy females between 9 and 26 years of age, in Sub-Saharan Africa.
- Trial name
- NCT01245764
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Genital Warts
Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts
The purpose of this study is to determine whether imiquimod creams are effective in treating external genital warts (EGW). The secondary objective of this study is to provide information on recurrence of EGW.
- Trial name
- NCT00735462
- Testing
- 2.5% imiquimod cream, 3.75% imiquimod cream
- Where
- 43 sites in United States
- Volunteers
- 511 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Genital Warts, Human Papilloma Virus
Typing of Human Papilloma Virus (HPV) From Female Genital Warts
This is a longitudinal observational study of women presenting to Groote Schuur Hospital with genital warts. The study will evaluate the socio-demographic characteristics of the women using a structured questionnaire.
- Trial name
- NCT01192282
- Testing
- Medical / Surgical Treatment
- Where
- South Africa
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- University of Cape Town
Verruca, Warts
Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study
The purpose of this study is to investigate topical treatment with Veregen™ 15% ointment as a single therapeutic agent and compare it to combination therapy with Veregen ™ 15% ointment and a single destructive treatment by…
- Trial name
- NCT02622568
- Testing
- Veregen only, Cryotherapy and Veregen
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Verruca Vulgaris, Molluscum Contagiosum Skin Infection
Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca
This study is going to test a cold atmospheric plasma device (CAP), in particular a floating electrode-dielectric barrier device (FE-DBD), to treat warts and molluscum.
- Trial name
- NCT05070754
- Testing
- Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP), Cryotherapy, Canthardin Collodion
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Medical University of South Carolina
Common Wart
A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
The primary objective of this study is to evaluate the effectiveness of A-101 compared to Vehicle when applied to 1 Target common wart on the trunk or extremities twice a week.
- Trial name
- NCT03278028
- Testing
- A-101 Topical Solution, A-101 Vehicle Solution
- Where
- 16 sites in United States
- Volunteers
- 159 people
- Sponsor
- Aclaris Therapeutics, Inc.
Warts, Genital, Neoplasms, Anal
Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064)
The purposes of this phase 3, double-blind, placebo-controlled clinical study are to evaluate the efficacy of V503 in preventing human papillomavirus (HPV)-related anogenital persistent infection, and to evaluate the…
- Trial name
- NCT04635423
- Testing
- V503
- Where
- 22 sites in Japan
- Volunteers
- 1,059 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Genital Warts
Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
The purpose of this study is to determine whether imiquimod creams are effective in treating external genital warts (EGW). The secondary objective of this study is to provide information on recurrence of EGW.
- Trial name
- NCT00674739
- Testing
- Imiquimod, 3.75% imiquimod cream
- Where
- 30 sites in United States
- Volunteers
- 470 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Warts, Human Papilloma Virus
Candin Safety & Efficacy Study for the Treatment of Warts
The primary objective of this study is to determine the safety of Candin® (Candida albicans Skin Test Antigen) at a 0.3 ml dose level at up to 6 monthly injections for treating common warts (Verruca vulgaris).
- Trial name
- NCT01757392
- Testing
- Candida albicans Skin Test Antigen
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Nielsen BioSciences, Inc.
WHIM Syndrome
A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
This is a Phase 2 study with an initial 24-week Treatment Period and an Extension Phase. The primary objectives of this Phase 2 study are to determine the safety, tolerability, and dose selection of mavorixafor in participants…
- Trial name
- NCT03005327
- Testing
- X4P-001
- Where
- 2 sites in United States, Australia
- Volunteers
- 8 people
- Sponsor
- X4 Pharmaceuticals